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THE HUMAN GENOME DIVERSITY PROJECT
AND THE NEW BIOLOGICAL IMPERIALISM
Cindy Hamilton*
I. INTRODUCTION
Few industries in the world possess the potential for
exponential growth enjoyed by biotechnology.1 Responding to
the ceaseless pressure for answers to enigmatic questions of
the sources and cures for disease, the industrialized world
pioneers advances in biotechnology faster than responsible
international social or legal policy can be devised to monitor
the advances.!
This trend of innovation has been provided in large part
courtesy of material gathered from diverse and isolated
regions of the globe in a process referred to as
"bioprospecting."3 In a style reminiscent of prospectors of the
past, bioprospectors are alerted to previously "undiscovered"
resources derived from the plants and animals of developing
countries and quickly apportion these materials for science,
and in the case of pharmaceutical companies, for profit.4 The
most popular and potentially profitable form of bioprospecting
targets not just the plant life of developing countries, but
those countries' indigenous human inhabitants.5
* Comments Editor, Santa Clara Law Review, Volume 41. J.D. candidate,
Santa Clara University School of Law; B.S., Santa Clara University.
1. See Sally I. Ifirst, Biopatents: A Sense of Order, 10 TRENDS IN
BIOTECHNOLOGY 269 (1992).
2. See Rural Advancement Foundation International [hereinafter RAFI],
The Patenting of Human Genetic Material (visited Jan. 30, 1994)
<http://rafi.org/web/allpub-one.shtml?dfl=allpub.db&tfl=allpub-one-frag.ptml&
operation=display&rol=recNo&rfl= 2 0 &rtl=20&usebrs=true>.
3. See Emily Marden, The Neem Tree Patent: International Conflict Over
the Commodification of Life, 22 B.C. INTL & COMP. L. REV. 279 (1999).
4. See id. at 280.
5. See Laurie Anne Whitt, Indigenous Peoples, Intellectual Property & the
New Imperial Science, 23 OKLA. CITY U. L. REV. 211, 218 (1998).
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The Human Genome Diversity Project ("HGDP"),6 a
poignant manifestation of this phenomenon, consists of an
international consortium of scientists, universities, and
governments organized to collect information on human
genome variation in an effort to understand the genetic
makeup of humanity.7
Clues about the evolution of humanity present
themselves most clearly in the genetic material of indigenous
populations throughout the world, as these populations have
evolved in relative isolation and provide a unique opportunity
for scientists to gain an understanding of the diversity of the
human genome.8 To implement the project, scientists collect
and study blood and tissue samples taken from hundreds of
indigenous communities around the world.9
Once scientists have collected the information, they will
use it to study the human genome variation in an effort to
understand human biological history, the biological
relationship among different human groups, and potential
causes and treatments for various human diseases. ° In
modern industrial society, newly discovered medical
"treatments" derived from the cells of the indigenous
(sometimes without their knowledge) often translate into
patents worth millions of dollars.1
Curing disease and expanding the wealth of scientific
knowledge relating to disease research are undeniably noble
causes. 2  Scientists have achieved these innovations,
however, at the expense of the indigenous, who scientists
almost never compensate for their resources while
multinational companies reap billions of dollars in profit."
Apart from the exploitation of their genetic material,
many indigenous populations also object to the imposition of
6. See Morrison Institute for Population and Resource Studies, Human
Genome Diversity Project: Frequently Asked Questions [hereinafter Morrison
Institute FAQ] (visited Oct. 26, 2000) <http://www.stanford.edu/group/morrinst/
hgdp/faq.html>.
7. See id.
8. See id.
9. See id.
10. See id. (The HGDP has specific research grants to study the molecular
causes for diseases such as diabetes, rheumatoid arthritis, and hypertension).
11. See Philip L. Bereano, Patent Pending: The Race to Own DNA, SEATTLE
TIMES, Aug. 27, 1995, at B5.
12. See Morrison Institute FAQ, supra note 6.
13. See Marden, supra note 3, at 280.
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Western theories of science and medicine that conflict with,
and seek to invalidate, traditional spiritual beliefs."' When
this occurs, Western science operates as a form of
bioimperialism where the dominant Western culture imposes
its ideology on indigenous populations inherently less
equipped to resist.5 While the HGDP's goal of eliminating
disease might be medically noble, it has proven naive and
offensive in both theory and implementation to many
indigenous groups around the world. 6
This comment will discuss the history of biocolonialism
and the long-standing relationship between Western science
and resources of indigenous populations internationally. 7
Next it will explain the history and methods of the HGDP and
other examples of bioimperialism that encroach on indigenous
human rights, and explain how conflicting belief systems lie
at the heart of the resistance. 8 This comment will discuss
how U.S. intellectual property law, which increasingly
influences the demand for indigenous genetic material, affects
the populations sampled. Currently, no international
organization governs human genetic testing. 9 This comment
will explore the necessity of regulation to preserve indigenous
human rights and propose an international organization most
qualified to take on this responsibility."
II. BACKGROUND
To appreciate why indigenous populations oppose groups
such as the HGDP, it is first necessary to understand the
history of the relationship between Western science and the
indigenous populations of the Third World.2' The recent
history of the Guajajara tribe of Brazil best illustrates the
phenomenon of biocolonialism.2" Over a hundred years ago
the Guajajara discovered that one of their native plants, the
14. See Whitt, supra note 5, at 237.
15. See Marden, supra note 3, at 280.
16. See Whitt, supra note 5.
17. See DARRELL A. POSEY & GRAHAM DUTFIELD, BEYOND INTELLECTUAL
PROPERTY: TOWARD TRADITIONAL RESOURCE RIGHTS FOR INDIGENOUS PEOPLES
AND LOCAL COMMUNITIES 53 (1996).
18. See Whitt, supra note 5.
19. See id.
20. See Convention on Biological Diversity, June 5, 1992, 31 I.L.M. 818.
21. See POSEY & DUTFIELD, supra note 17.
22. See id.
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Pilocarpus jaborandi, can treat glaucoma.23 For years the
Guajajara developed and honed the medicinal uses of
Pilocarpus, utilizing their tribal medicinal knowledge. 4
Today, the Pilocarpus is virtually depleted and unavailable to
the Guajajara while Brazil exports it annually for $25 million
as a glaucoma treatment, and this amount pales in
comparison to the revenues of the pharmaceutical company
that patented Pilocarpus.25
The situation of the Guajajara typifies Western science's
intervention with developing countries. 6 The current trend
in Western science involves harvesting not just indigenous
peoples' knowledge and resources, but their genetic
material." The controversial HGDP is one such group that
seeks to obtain genetic samples of the indigenous. 8
A. The Philosophy Behind the HGDP
The HGDP finds its roots in the Human Genome
Organization ("HUGO"). 9 In 1988 HUGO formed the Human
Genome Project, a billion-dollar international effort to map
and sequence the human genome.0 While the Human
Genome Project aims to sequence the human genome with
DNA taken mainly from individuals of North American and
European ancestry, HUGO coordinated the HGDP in 1994 to
study the variation in the human genome as found in the
genetic material of individuals from all over the world."'
The HGDP almost exclusively targets indigenous Third
World populations, referring to them as "Isolates of Historic
Interest."2 Indigenous populations constitute a particularly
attractive gene pool sample because of the isolation in which
they have developed over the centuries.3 Furthermore, these
populations, usually as a result of modernization and
urbanization, face extinction, compelling scientists to collect
"precious genetic information" such as DNA samples before
23. See id.
24. See id.
25. See id.
26. See Whitt, supra note 5, at 214.
27. See id.
28. See Morrison Institute FAQ, supra note 6.
29. See id.
30. See id.
31. See id.
32. See Whitt, supra note 5.
33. See Morrison Institute FAQ supra note 6.
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these populations disappear.34
The Human Genome Project can now grasp a vanishing
opportunity to preserve the record of our genetic heritage.
The genetic diversity of people now living harbors the clues to
the evolution of our species, but the gate to preserve these
clues is closing rapidly. 5
This has created a sense of urgency within the HGDP to
collect as many samples as possible from populations at risk
of dying out. 6 The assumption underlying this view offends
the indigenous community: that the efforts of the HGDP
would be better spent simply studying what remains of these
vanishing populations and accepting their fate as endangered
rather than working in a similar global effort to preserve
their longevity.87 The United Nation's Educational, Scientific,
and Cultural Organization ("UNESCO") International
Bioethics Committee agreed when they refused to endorse the
HGDP, finding that "although HGDP has 'expressed urgency'
in collecting samples from peoples in danger of cultural and
physical extinction, it had not expressed concern about their
extinction per se.""
This accusation of hypocrisy of the HGDP was echoed by
Tadodaho-Chief Leon Shenandoah of the Onondaga Council
of Chiefs, who, in refusing to allow genetic testing of the
Onondaga and Cayuga people, commented, "If there is
concern for our demise, then help us survive on our terms. '
Scientists will "immortalize" samples taken by the HGDP
in various gene banks located in the United States for future
34. See RAFI, supra note 2. Some populations that have been targeted
include the Plains Apache in Oklahoma, the rural Quechua tribe in Norte de
Potosi, Bolivia, aboriginal populations of Australia and New Guinea, and
ancient Native Americans from Sillwater Marsh and Pyramid Lake, Nevada.
See RAFI, U.S. Funding of Human Biodiversity Collections Carries on Despite
Contrary Scientific Advice (visited Nov. 14, 1997) <http://rafi.org/web/allnews-
one.shtml?dfl=allnews.db&tfl=allnews-one-frag.ptml&operation--display&rol=recNo&
rfl=4&rtl=4&usebrs=true>.
35. See L.L. Cavalli-Sforza et al., Call for a Worldwide Survey of Human
Genetic Diversity: A Vanishing Opportunity for the Human Genome Project, 11
GENOMICS 490 (1991).
36. See Whitt, supra note 5.
37. See RAFI, supra note 2.
38. Declan Butler, Genetic Diversity Proposal Fails to Impress International
Ethics Panel, NATURE, Oct. 5, 1995, at 373.
39. Letter from Chief Leon Shenandoah and the Onondaga Council of Chiefs
to Johnathan Friedlaender, Division Director, National Science Foundation
(Nov. 18, 1993) (on file with NativeNet (visited Oct. 28, 2000)
<http://nativenet.uthscsa.edu/archive/nl/9312/0122.html>).
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study." The technique of cell conservation will be used to
keep cells alive and capable of multiplying, thus generating
an unlimited amount of DNA.4 The HGDP will make these
samples available internationally to research scientists.42 The
expectation is that information obtained from scientific
studies will be available to other scientists and to the
populations being studied.43  Cell samples collected by the
HGDP will be available publicly, not just to HGDP
researchers but also to anyone who wishes to access this
information." This wide distribution of genetic material
creates problems because, although HGDP researchers must
agree not to patent collected material, no such obligation
exists for other scientists.' HGDP researchers may not
explain to subjects that, while they themselves will not patent
the samples, those samples may be widely distributed to
scientists who will seek patents.4"
According to the HGDP, the participation of indigenous
groups may hinge on the potential for future medical
advances. 47  However, aware that the potential long-term
gratification might not provide enough persuasion to
participate, the HGDP offers immediate compensation in the
form of medical testing and vaccinations usually not made
available to many remotely located indigenous populations.48
From this arises the threat that indigenous people,
unfamiliar with Western science and the potential for
exploitation of their genetic material, may acquiesce to eager
and persuasive scientists without comprehending the full
extent of their compliance.4"
40. See Morrison Institute FAQ, supra note 6.
41. See id.
42. See id.
43. See id.
44. See RAFI, Phase II for Human Genome Research (visited Jan. 21, 2000)
<http://rafi.org/web/allpub-one.shtml?dfl=allpub.db&tfl=allpub-one-frag.ptml&
operation=display&rol=recNo&rfl=70&rtl=70&usebrs=true>.
45. See id.
46. See id.
47. See Morrison Institute FAQ supra note 6.
48. See id. An illustration of the services offered include those by Dr.
Cavalli-Sforza, a founder of the HGDP, who worked for many years with
populations in central Africa. He discovered that many of the people he saw
suffered from yaws, a rare but terrible skin disease. On subsequent visits, he
brought large amounts of antibiotics that cured this affliction. See id.
49. See RAFI, Diverse Group Joins in Washington to Oppose U.S.
Government Funding for the HGDP (visited Sept. 11, 1996)
<http'/ 6 4.4.69.14/weh/allnews-one.shtml?Dfl=alnews.db&tfl=allnews.one-frag.pt
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"Researchers who said they were affiliated with the HGDP
offered us diabetes tests while they took samples of our
blood," says Leonor Zalabata Torres, an Arguaco leader
from northern Columbia, "we agreed; but had no idea that
a few months later, our blood would be in the U.S. being
tested in the very same laboratory that patented the cells
of an indigenous person from Papua New Guinea. I'm
alarmed that Western laws allow this, and we are not
satisfied that the HGDP will be capable of insuring that
our blood won't be exploited in ways of which we do not
approve."
50
Whether any long-term benefits exist to the sampled
populations remains unknown.51 The hype and controversy
generated by the HGDP has had far-reaching effects, and
some developing countries actually seek out HGDP research
in their area, based on the supposed medical benefits
resulting from research.52 For example, scientists in sub-
Saharan Africa face obstacles of scarce funding for genetic
research and endorse the HGDP for the technology and
scientific expertise a HGDP study would bring to the area."
There are very few population geneticists in Africa and
genome diversity studies have low priority in developing
countries ... [Clollaborations between scientists in the
developed and developing worlds need to be strengthened
and efforts [need to be] made to train and encourage
researchers in developing countries. Genetic testing of
many thousands of DNA samples obtained from a large
range of sub-Saharan African populations will provide
useful data on genetic epidemiology.
5 4
B. The Problem of Consent
Cultural differences also complicate the process of
obtaining consent from the populations sampled.55  The
Council of International Organizations for Medical Sciences
defines informed consent as follows: "consent is informed
when it is given by a person who understands the purpose
ml&operation=display &rol=recNo&rfl=l&rtl=l&usebrs =true>.
50. Id.
51. See Morrison Institute FAQ, supra note 6.
52. See T. Jenkins & H. Soodyall, Remarks at the Fifth South-North Human
Genome Conference, Windhoek, Namibia (Feb. 1999).
53. See id.
54. Id.
55. See Morrison Institute FAQ, supra note 6.
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and nature of the study, what participation in the study
requires a person to do and to risk, and what benefits are
intended to result from the study."56 This policy standard is
somewhat attainable when attempting to obtain consent from
subjects familiar with Western science," but sampling
indigenous populations unfamiliar with Western science
presents the most challenging of situations for obtaining
informed consent.58
Many indigenous people, such as the Maori, view their
genetic material as their "life spirit," a unique spiritual realm
comprised of both ancestors and future generations-a
combination of history and spirituality that is unique to each
individual. 9 The Maori "life spirit" concept comes in direct
conflict with Western science, which emphasizes uniformity of
human genetic material, minus the subtle differences that lie
at a molecular level.6 °
The HGDP's Model Ethical Protocol for Collecting DNA
Samples emphasizes the importance of obtaining informed
consent from subjects. However, the HGDP makes no
apologies for the "unattainable perfection" of truly informed
consent.6
Unresolved issues such as the informed consent policy
have plagued the HGDP since its inception and infuriated
indigenous rights advocates worldwide. 2 After learning of
the HGDP, the World Council for Indigenous Peoples
("WCIP") and Rural Advancement Foundation International
56. COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL STUDIES,
INTERNATIONAL GUIDELINES FOR ETHICAL REVIEW OF EPIDEMIOLOGICAL
STUDIES (1991).
57. See Morrison Institute FAQ, supra note 6.
58. See Morrison Institute for Population and Resource Studies, Human
Genome Diversity Project: Model Ethical Protocol for Collecting DNA Samples
[hereinafter Morrison Institute Protocol] (visited Dec. 21, 2000) <http://www.
stanford.edu/group/morrinst/hgdp/protocol.html>.
59. See Letter from Aroha Mead, Director, International Association of the
Mataatua Declaration, to Dr. Darrell Macer, Sub-Committee on Population
Genetics, UNESCO International Bioethics Committee, UNESCO-Bioethics &
Human Population Research (July 29, 1995).
60. See id.
61. See Morrison Institute Protocol, supra note 58. "Given the isolation of
many of the populations involved, their non-literacy, and lack of acquaintance
with a cosmology grounded in molecular biology, obtaining informed consent
will be a contrived exercise, which, aside from human rights issues, may have
some unforeseen results." Margaret Lock, Editorial: Interrogating the Human
Genome Diversity Project, 39 SOC. SCI. & MED. 603, 605 (1994).
62. See RAFI, supra note 44.
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("RAFI") protested the potential abuses and
commercialization of human genetic material before the
United Nations Human Rights Conference in Vienna in June
1993.6" The groups called for a moratorium on projects that
could result in the patenting of human genetic material until
ethical considerations of the practice could be addressed.64
Two months later, indigenous groups discovered that the
U.S. government had applied for U.S. and international
patents on the cells of a Guaymi Indian woman from Panama
without the consent of the woman, the Guaymi Indians, or
the Panamanian government.65  Outraged, the Guaymi
General Congress gained international support from RAFI,
the WCIP, and the European Greens, who introduced an
emergency resolution into the European Parliament, calling
for a common European position opposing human patenting.66
Besieged by international criticism, the U.S. government
withdrew its claim to the patentY.
The effects of intervention by the international
community proved temporary.68 Despite the outrage over its
Guaymi patent application, the U.S. government again
patented a cell line from a man in Papua New Guinea. 9 No
less disturbed by this second attempt, international bodies
again protested and the U.S. government finally disclaimed
the patent.
7°
C. Biotechnology and the New Imperialism
The actions of the U.S. government become less
surprising when confronted with concrete proof of the
profitability of patenting indigenous genetic material. 7' The
asthmatic inhabitants of the South Atlantic island Tristan da
Cunha proved lucrative to researchers when their blood
63. See RAFI, supra note 2.
64. See id.
65. See id.
66. See id.
67. See id.
68. See Craig Benjamin, Gene Hunting Criticized by U.S. Research Council,
NATIVE AM. J., Feb. 3, 1999.
69. See id.
70. See id.
71. See The Spunk Library, Indigenous Person from Papua New Guinea
claimed in U.S. Government Patent (visited Oct. 4, 1995) <http://www.spunk.
org/library/colon/spOO1144.txt>.
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samples offered the potential for asthma treatment."
Researchers sold the blood to a California-based company,
which subsequently sold its biotechnology rights to the
German pharmaceutical company, Boehringer Ingelheim, for
$70 million.73
Indigenous people find the piracy of their genetic
material offensive for reasons beyond the marketing of their
cells without permission; for people such as the Guaymi, it
violates their beliefs. 4 According to Isidro Acosta, President
of the Guaymi General Congress, "I never imagined people
would patent plants and animals. It's fundamentally
immoral, contrary to the Guaymi view of nature, and our
place in it. To patent human material . . . to take human
DNA and patent its products.., that violates the integrity of
life itself, and our deepest sense of morality."7"
The differing ideologies of the industrialized world and
indigenous populations of the Third World lie at the heart of
the controversy over the commodification of human genetic
material." Many indigenous populations consider their
genetic material as sacred as their spiritual beliefs and
integral to their identification as people and members of a
population.77 In contrast, the U.S. government allows, and
even encourages, the patenting of human genetic material but
denies any claim of ownership to the people from whom the
samples derive.78
Even indigenous groups not opposed to the sampling of
their genetic material on moral grounds find fault with the
U.S. system of patenting that alleges to compensate the
indigenous for any discoveries that result. 9 As demonstrated
by the U.S. government's Guaymi patent, many indigenous
people would not receive any sort of financial gains that could
be reaped by their population in the billion-dollar
72. See id.
73. See id.
74. See id.
75. RAFI, supra note 2.
76. See Whitt, supra note 5, at 240.
77. See id.
78. See Moore v. Regents of the Univ. of Cal., 51 Cal. 3d 120, 154-64 (1990)
(sustaining dismissal of the cause of action based on conversion).
79. See RAFI, Biopiracy Update: The Inequitable Sharing of Benefits (visited
Sept. 30, 1997) <http://rafi.org/web/allpub-one.shtml?dfl=allpub.db&tfl=allpub-
one-frag.ptml&operation=display&rol=recNo&rfl=28&rtl=28&usebrs=true>.
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pharmaceutical business."
Indigenous communities may view skeptically the
promises for royalties extended by American researchers,
given the California Supreme Court decision involving Seattle
businessman John Moore. Moore lost ownership rights (and
thus any possibility for royalties) over his cells after
researchers removed them from his body and patented them.8
As Moore commented to the National Academy of Science
("NAS") committee on the HGDP, "Do you think a system that
could not protect me will protect the rights of peoples or
individuals that live in other countries?"
82
Although research conducted under the HGDP has not
yet resulted in the issuance of a patent, and its members
strongly maintain that "it seeks knowledge, not profit," the
possibility of patenting samples still exists.83  Scientists
involved in the HGDP defend the project saying that they
conduct research for a purely scientific purpose (e.g., in the
pursuit of knowledge) and not for the discovery of treatments
to patent.8' This response has not appeased indigenous rights
activists who maintain "knowledge in and of itself is not
immoral; however, the potential for adverse effects from the
acquisition and utilization of this knowledge has contributed
to this moral dilemma."5
The U.S. National Science Foundation ("NSF"), one of the
HGDP's supporters, reported these ethical and scientific
shortcomings in the results of its thirty-month investigation.86
The National Research Council ("NRC") called the HGDP's
model ethical code for collecting samples inadequate, noting
80. See id.
81. See Moore, 51 Cal. 3d at 125-47.
82. RAFI, supra note 79. A number of HGDP studies have been approved
and implemented in other countries, including Tibet, New Guinea, Bolivia, and
Western Samoa. See RAFI, U.S. Funding of Human Biodiversity Collections
Carries on Despite Contrary Scientific Advice (visited Nov. 14, 1999)
<http'//rafi.org/web/aUnews-one.shtml?dfl=allnews.db&tfl=allnews-one-frag.ptml
&operation=display&rol=recNo&rfl=4&rtl=4&usebrs=true>.
83. See Morrison Institute FAQ, supra note 6.
84. See id.
85. Elizabeth Clay McPherson, Ethical Implications of the Human Genome
Diversity Project, 8 NURSING CONNECTIONS 36, 42 (1995).
86. See RAFI, supra note 82. Support from the NSF's Physical
Anthropology Program for human biodiversity activities nearly doubled between
1995 and 1997, and in the time between when the investigation was
commissioned and the evaluation was received, nearly fifty-two percent of the
NSF's grant money went to fund HGDP studies. See id.
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that it would be "unethical for scientists to use indigenous
blood samples for purposes other than that originally agreed
to by research subjects."' v For example, blood samples taken
from youth in Western Samoa appeared to have been taken
by virtue of a NSF grant and used for purposes of developing
a patent.8 Despite its condemning report, the NSF has
continued to fund HGDP research. "
Internationally, however, resistance among indigenous
rights groups is rapidly gaining momentum.9" Since the
United States has repeatedly demonstrated indifference
towards the plight of the indigenous in protecting their
genetic material, indigenous populations looked to the
European Union and other international intergovernmental
organizations for support.9
The United Nations took the initiative when it issued the
Draft United Nations Declaration on the Rights of Indigenous
Peoples, stating that the genetic resources of indigenous
people deserve special protection from bioprospectors.92
Subsequently, on November 11, 1997, UNESCO adopted
the Universal Declaration on the Human Genome and
Human Rights ("Declaration"). 3 Focusing on the duties of
genetic researchers, the Declaration relies on international
human rights policy, intellectual property, and environmental
texts.94 The Declaration demands that genetic research
respect the human rights of the indigenous people through
meticulous assessment of any potential risks for those
involved.8  The Declaration balances dedication to the
protection of human rights with a positive stand toward
87. RAFI, supra note 82.
88. See id.
89. See id.
90. See RAFI, Diverse Group Joins in Washington to Oppose U.S.
Government Funding for the HGDP (visited Nov. 11, 1996)
<http://rafi.org/web/allnews-one.shtml?dfl=allnews.db&tfl=allnews-one-
frag.ptml&operation=display&rol= recNo&rfl=l&rtl=l&usebrs=true>.
91. See DRAFT UNITED NATIONS DECLARATION ON THE RIGHTS OF
INDIGENOUS PEOPLES, U.N. COMMISSION ON HUMAN RIGHTS, 46th Sess.,
preamble para. 6, U.N. Doc. E/CN.411995/2, revised by U.N. Doc.
E/CN.4/Sub.2/1994156 (1995), reprinted in 34 I.L.M. 541 (1995).
92. See id.
93. See Universal Declaration on the Human Genome and Human Rights,
U.N. Educational, Scientific, and Cultural Organization, Gen. Conf., 29th Sess.
(1997), available at <http://unesdoc.unesco.org/images/0010/001096/109687eb.
pdf>.
94. See id.
95. See id.
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human genetic testing, foreseeing "vast prospects for progress
in improving the health of individuals and humankind as a
whole."
9 6
The Declaration imposes this balancing test on scientists,
who must consider the needs of the indigenous populations
they study above their research.97 "No research or research in
its applications concerning the human genome, in particular
in the fields of biology, genetics and medicine, should prevail
over respect for the human rights, fundamental freedoms and
human dignity of individuals or, where applicable, of groups
of people."" But many indigenous populations feel that the
two goals, advancement of genetic research and preservation
of indigenous human rights, cannot co-exist. Since the
"experts" involved in drafting the Declaration hail from the
research and scientific community, the drafters cannot
adequately represent or protect indigenous people's views. 1' °
The Council of Europe Convention on Human Rights and
Biomedicine ("Convention") took a stronger approach to
protecting human rights when it established the protection of
the dignity of human beings as a fundamental human right.'
While the Declaration called for a balancing of interests, the
Convention explicitly stated that the protection of human
rights for indigenous people has priority over the pursuit of
scientific research, stating "the interests and welfare of the
human being shall prevail over the sole interest of society or
science."' 2  The Convention also more progressively
approached the realities of the financial incentives behind
genetic research by prohibiting the use of the body or its
genetic materials for monetary gain.03
Despite its strong position supporting the protection of
human rights of indigenous people,' the Convention offered
little practical application of the treaty to the jurisprudence of
the European Community, with injunctions and punishment
96. Id.
97. See id.
98. Id.
99. See Dinah Shelton, Challenges to the Future of Civil and Political
Rights, 55 WASH. & LEE L. REV. 669, 676 (1998).
100. See id.
101. See Council of Europe: Convention on Human Rights and Biomedicine
and Explanatory Report, April 4, 1997, 36 I.L.M. 817 (1997).
102. Id. at 821.
103. See id at 823.
104. See id.
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as methods of enforcement. 5 However, its limited scope
underscores the Convention's inadequacy; scientists commit
biopiracy throughout the world, but the Convention applies to
only the twenty-two European states who signed it.'0°
III. IDENTIFICATION OF THE PROBLEM
Each of the questionable occurrences of scientists
attempting to patent indigenous genetic material and the
continuation of the HGDP in the scientific world despite
significant international criticism,"' culminate in a troubled
system that values medical advances over human rights.' °
Programs like the HGDP proceed despite their lack of
external supervision which would include sanctions for
protocol violations.' 9  A desperate need exists for an
international policy recognizing indigenous rights and
supervising the collection of human genetic material
accordingly.' 0°
Clearly, a systematic method is necessary to protect the
interests of indigenous populations and regulate the
bioprospecting industry worldwide."' Although several
international bodies have intervened in times of crisis," ' no
one international organization claims to have authority over
an industry that expands more quickly than modern legal and
social policy can govern.1
IV. ANALYSIS
The HGDP has been criticized for years over a number of
unresolved problems."' Even the most basic right of the
indigenous populations studied, the right to consent to have
scientists take samples from them, is flawed."5 The HGDP
sets forth, in its Model Ethical Protocol, the standards that it
will use in obtaining samples. The HGDP devotes a
105. See id.
106. See Council of Europe, supra note 101.
107. See RAFI, supra note 44.
108. See id.
109. See id.
110. See id.
111. See id.
112. See RAFI, supra note 2.
113. See RAFI, supra note 44.
114. See id.
115. See Morrison Institute Protocol, supra note 58.
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substantial portion of those standards to the importance of
obtaining consent from any group or individual being
studied.11  As discussed earlier, indigenous populations
present a particularly challenging situation when seeking
informed consent."' Differing ideologies of the genetic
makeup of humans, language barriers, and the general
complexity of explaining the HGDP present only a few
examples." 8 The scientists behind the HGDP acknowledge
the difficulty in obtaining truly informed consent, but
nevertheless remain unapologetic in their determination to
continue the project."9 Presumably, the HGDP contents itself
with settling for a lesser standard when it comes to obtaining
the informed consent of its subjects.'
Even indigenous subjects familiar with Western science's
quest for their genetic material may misunderstand the
ultimate fate of the samples they provide.' Although HGDP
researchers may truthfully explain to subjects that they will
not patent their material, once these samples enter the public
domain, they become difficult to regulate. 22
Another challenge to the HGDP policy of informed
consent also resides in the Model Ethical Protocol, a guideline
which recognizes the necessity of consent from both
individuals and the population as a whole,' 3 but fails to
comprehend the divisiveness that could result within
indigenous populations.' It fails to address the problems
that could arise, for example, when all members of a tribe's
council elders do not agree as to whether the HGDP should be
allowed to take samples within the tribe.'
It will be questionable if consent really exists by both
members of the population and individual members,
especially where government officials exert control over local
indigenous populations. 6  Aroha Mead, Director of the
International Association of the Mantaatua Declaration, said,
116. See Morrison Institute FAQ, supra note 6.
117. See id.
118. See id.
119. See id.
120. See id.
121. See RAFI, supra note 44.
122. See Morrison Institute FAQ, supra note 6.
123. See Morrison Institute Protocol, supra note 58.
124. See Whitt, supra note 5, at 242.
125. See id.
126. See Letter from Aroha Mead to Dr. Macer, supra note 59.
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"The (Diversity Project) and other similar-type activities can
serve to divide, and cause irreparable damage, to the ability
of the indigenous communities to trust each other, let alone
trust others.' 27
The issue of obtaining consent, however, links the
motivation of indigenous populations when they agree to
participate in the genetic testing.'28 Arguably, indigenous
populations would only subject themselves to Western
scientists for the short-term benefits of medical treatment
and the long-term possibility of cures for their most
debilitating diseases.'29 Herein lies the next problem with the
current state of genetic testing because, in actuality, only a
remote possibility exists that any medical advances
discovered from indigenous populations will prove beneficial
to them.3 9 According to Maori activist Aroha Mead, science
"is only of use if it improves the quality of life and society.
Without that, it serves no useful purpose to humanity, only a
purpose for a minority exclusive group of western
professionals, possibly at the expense of the unity and
survival of indigenous communities struggling to remain
intact."''
Any new medical applications that do result will most
directly (financially) benefit the scientist who discovers them,
the pharmaceutical company that manufactures them, 32 and
the people who can afford expensive medication and genetic
testing-primarily not the indigenous populations who
provide the samples.' "The enticement of potential medical
benefits is an empty promise which will be used to gain access
to communities for the collection of samples."3 4
Sadly, some indigenous populations so desperately need
the short-term benefits offered by projects like the HGDP
that they embrace the project's presence even if its practice
conflicts with their indigenous beliefs.'35 Scientists from
127. Id.
128. See Whitt, supra note 5.
129. See id.
130. See Morrison Institute FAQ, supra note 6.
131. Letter from Aroha Mead to Dr. Macer, supra note 59.
132. See Whitt, supra note 5, at 228.
133. See id.
134. Debra Harry, The Human Genome Diversity Project, 8 ABYA YALA NEWS
14 (1994).
135. See Jenkins & Soodyall, supra note 52. Although the African scientists
recommending the HGDP are not tribal leaders directly involved in making the
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places such as Africa acknowledge the "ethical issues"
involved with the HGDP but have perhaps been seduced by
the lure of technology and scientific attention that would be
brought to research-deficient sub-Saharan Africa-research
that would otherwise be impossible.136
The issue of patenting presents yet another complication
hindering the HGDP from being a purely scientific and
educational endeavor.'37 The HGDP takes a naive stance in
regard to patenting when it claims "it is not clear whether
any commercial products are likely to emerge from its
samples or data."3 ' Given the current state of bioprospecting
and the wealth of medically valuable information already
obtained, the distinct possibility exists of discovering new
treatments leading to a commercial product.3 '
Clearly, a more sophisticated approach to the complex
issues surrounding the ethical implications of sampling
indigenous genetic material is necessary to protect the
populations studied. 4 ° In its current form, the HGDP expects
indigenous populations to assume the risk for a number of
harms that could result with little, if any, benefit returning to
them.
41
The HGDP, a self-governing organization, functions
independently of any international organization that would
seek to regulate it.' 41 All groups that engage in genetic
testing, whether scientific or governmental, share this
characteristic.' Clearly, an international organization
empowered to regulate genetic sampling is necessary.144
International bodies have intervened when prompted by
indigenous communities, 4 ' but the effects of their
decision of whether or not to consent to the sampling, there is sufficient
evidence that these scientists are influential enough in the community so that
their recommendation might persuade the indigenous tribes to agree to be
studied by the HGDP. See id.
136. See id.
137. See Morrison Institute FAQ, supra note 6.
138. Id.
139. See RAFI, supra note 44.
140. See id.
141. See Whitt, supra note 5, at 228.
142. See RAFI, supra note 44.
143. See id.
144. See id.
145. See RAFI, supra note 2. Groups such as RAFI, the WCIP, and the
European Parliament successfully prevented numerous patent applications
derived from members of indigenous populations, including the Guaymi patent
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intervention have proved temporary, and a more permanent
solution is the only feasible way to contain genetic testing.4"
V. PROPOSAL
The Convention on Biological Diversity ("CBD"), which
claims a "comprehensive approach to biodiversity,"47 but
distances itself from any control over projects like the HGDP,
can provide a solution. The CBD monitors plant and animal
studies throughout the world, and although the CBD purports
to "[encompass] all ecosystems, species, and . . . genetic
resources," the Second Conference of the Parties ("COP")
specifically issued a statement excluding humans and human
genetic resources. 4'
Despite their prior disavowal, the CBD remains a viable
organization powerful enough to improve the international
system of bioprospecting for human genetic resources,14 9 if
only it would claim responsibility. Originally founded by the
United Nations Environment Programme ("UNEP"), 168
states have signed the CBD." ° The CBD serves as an ideal
candidate and model for any organization that would regulate
human genetic sampling for three reasons: its scope, its goals,
and its method of implementation.'
A. Scope
The CBD is comprehensive in the sense that it builds on
existing treaties that focused on single areas of biodiversity,
such as conservation or international trade, and combines
them into one international organization.'52 The strength of
its interdisciplinary approach, combined with its widespread
discussed in Part II.B-C above. See id.
146. See RAFI, supra note 44.
147. See Convention on Biological Diversity, An Introduction to the
Convention on Biological Diversity (visited Dec. 27, 2000) <http://www.biodiv.
org/press/prlO-95.html>.
148. See United Nations Conference on Environment and Development:
Convention on Biological Diversity, June 5, 1992, 31 I.L.M. 818 (1992);
Convention on Biological Diversity, Background to the Convention (visited Nov.
21, 2000) <http'/www.biodiv.org/doc>.
149. See Convention on Biological Diversity, supra note 148.
150. See United Nations Conference on Environment and Development,
supra note 148.
151. See id.
152. See id.
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international acceptance," 3 provide the most effective means
of obtaining a consensus on controversial biotechnology
issues.
Realistically, industrialized countries will continue to
seek patents on indigenous resources, knowledge, and genetic
material."' The CBD acknowledges the importance of
encouraging new technology tempered with the concern that
resources remain unexploited in its three goals: conservation
of biodiversity, sustainable use of the components of
biodiversity, and equitable sharing of benefits arising from
the use of genetic resources.' All are critical to an
organization that would seek to manage the current state of
human genetic bioprospecting"'
B. Goals
Particularly applicable to the sampling of human genetic
material is the CBD's third goal of equitable distribution of
benefits.5 7 As previously demonstrated, indigenous medicine,
seeds and knowledge have been commodified without notice
or compensation to the community from which the samples
are taken.
The CBD acknowledges that when microbes, plants, or
animals are commercially distributed, the country from which
they came should participate and benefit. 9 This recognition
has manifested in the form of bilateral contracts, where
indigenous populations negotiate for percentages of profits
from the sale of any treatment that may result from sampled
biological material.60
Unfortunately, the intention to equitably distribute
benefits developing from the commodification of indigenous
materials has yet to be realized.'6' The CBD's Article 8, which
states that indigenous communities must be compensated
fairly, has been criticized as rhetoric by indigenous groups.6 2
As an example, bioprospectors from the U.S. government-
153. See Convention on Biological Diversity, supra note 148.
154. See RAFI, supra note 2.
155. See Convention on Biological Diversity, supra note 148.
156. See RAFI, supra note 44.
157. See Convention on Biological Diversity, supra note 148.
158. See RAFI, supra note 2.
159. See Convention on Biological Diversity, supra note 148.
160. See RAFI, supra note 79.
161. See id.
162. See id.
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financed International Cooperative Biodiversity Group
offered indigenous populations of Peru a share of one quarter
of one percent of profits resulting from products based almost
entirely on indigenous knowledge and resources,.6 while
pharmaceutical companies pocketed the vast majority of the
profits."'
Many developing nations, frustrated with Western
science's acquisition and subsequent patenting of their
indigenous plant materials, have threatened to discontinue
access to their natural resources until Western researchers
and conglomerates offer a more equitable share of profits.'
Indian authorities, for example, are already working to make
knowledge of traditional plant and other natural resources
less available for acquisition by foreign companies. 6
If developing nations took a similar position with respect
to their human genetic material, scientific research involving
indigenous communities would cease, hindering medical
research and valuable pharmaceutical patents. 7 Faced with
this threat, pharmaceutical companies would have to choose
between equitable profit sharing or no profits at all.'68 Given
the symbiotic nature of their relationship, it is in the best
interest of both developing countries and the Western world
to reach a compromise with respect to equitable profit
sharing.9 The first step in the process is for the United
States to revise its current practices of compensation to
developing countries" Perhaps the threat of being cut off
from future resources that could result in biological advances
would compel the United States to sign on to the CBD and
share resulting benefits more equitably. 17
An agreement reached in the United States between the
Diversa Corporation and Yellowstone National Park could
serve as a model for how to quantify an appropriate
percentage of profits to return to indigenous communities. 71
163. See id.
164. See id.
165. See Anil Agarwal & Sunita Narain, Pirates in the Garden on India, NEW
SCIENTIST, Oct. 26, 1996, at 14.
166. See id.
167. See Marden, supra note 3, at 295.
168. See id.
169. See id.
170. See id.
171. See id.
172. See RAFI, supra note 79.
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Unique heat-seeking microorganisms caught the attention of
the American pharmaceutical company Diversa,"' which
negotiated a settlement whereby Yellowstone received ten
percent of sales in royalties from the project's developments of
this natural resource."4 If the United States demands such a
handsome percentage from the prospecting of organisms they
did not even cultivate, the logical extension is that indigenous
agriculture and medicinal knowledge, carefully honed and
developed over thousands of years, should have a value of at
least ten percent of the total profits."'
Although the CBD has not yet realized its full potential,
each COP continues to improve and strengthen its
commitment to establishing protocols to equitably monitor
the field of biodiversity internationally.' 6 To extend the CBD
to regulate the field of human genetic diversity testing would
be natural for an international body with so much expertise
in finding ethical solutions to situations involving
biodiversity."' The same methods that are used to
compensate indigenous people fairly for their natural
resources should apply to their genetic resources as well.' 8
C. Implementation
As demonstrated by the deficiencies in other
international organizations seeking to protect the human
rights interests of indigenous people, the protocols introduced
in a treaty are only as effective as its methods of
implementation and enforcement. 9 The third strength of the
CBD is found in its ability to sufficiently implement the policy
it prescribes through its status as a legally binding
document.'8 °
As parties to the CBD, states are bound under Article 27
to settle disputes that may arise over a possible human rights
violation from genetic testing first through negotiation and
mediation.'8 ' If these methods of dispute resolution do not
173. See id.
174. See id.
175. See id.
176. See Convention on Biological Diversity, supra note 148.
177. See id.
178. See RAFI, supra note 79.
179. See DRAFT UNITED NATIONS DECLARATION ON THE RIGHTS OF
INDIGENOUS PEOPLES, supra note 91.
180. See Convention on Biological Diversity, supra note 148.
181. See id.
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resolve the conflict to the satisfaction of both parties, the case
may be heard before the International Court of Justice with
the result binding on both parties.82
This method of enforcement insures: 1) a fair
consideration of the issues presented and 2) a definitive
action to remedy any international human rights violations
that may occur.'83 Both elements are necessary to ensure that
the standards of the CBD are upheld and functioning
efficiently.1
4
The implementation of the CBD goes one step further
when it recognizes the influence that patents and intellectual
property rights may have on the execution of the policies of
the CBD and calls for each state's legislation to conform to its
policies.'85 "[Each state] shall cooperate in this regard subject
to national legislation and international law in order to
ensure that such rights are supportive of and do not run
counter to its objectives."'86 Requiring both individual state
legislation and international policy to correspond to the treaty
takes preventative measures reducing the possibility that
violations will occur."'
D. Compromise and Preserving Indigenous Beliefs
While a comprehensive protocol to protect the human
rights of indigenous populations would be effective for those
who agree to participate, it still presents a dilemma for those
indigenous communities who seek to resist the imposition of
Western bioprospecting.'88  It is inherently difficult to
challenge the ideology of Western intellectual property law'89
"without accepting its own terms of reference and hence
losing the battle before it has begun."' Indigenous people
such as the Maori view their genes as a "life spirit," consisting
of both past and future generations, and thus incapable of
being owned, bought, sold, or patented.'
182. See id.
183. See id.
184. See id.
185. See Convention on Biological Diversity, supra note 148.
186. Id.
187. See id.
188. See Whitt, supra note 5, at 151.
189. See id.
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[T]he indigenous and western scientific philosophies differ
on this fundamental point . . . it is the difference in
understanding of the origin of humanity, the
responsibility of individuals, and the safety of future
generations which sits so firmly at the core of indigenous
opposition to the [HGDPI . . . this type of research
proposes to interfere in a highly sacred domain of
indigenous history, survival and commitment to future
192generations.
Thus indigenous people like the Maori must acknowledge
the Western ideology of genetic ownership before they can
successfully ward off its encroachment.9
VI. CONCLUSION
The issues presented by the HGDP and the scientific
pursuit of indigenous genetic material are as complex
ethically, morally, and legally as any that exist in
international law. Indigenous populations, historically
exploited for their land, resources, and knowledge by Western
imperialism, are now pursued for their genetic material."'
Projects like the HGDP, despite its good intentions medically,
occupy a position on a continuum of cultural imperialism that
seeks to exploit indigenous communities while offering almost
nothing in return.'95 Few communities in the world are as ill-
equipped as the indigenous when attempting to protest their
participation in experiments,'96 yet their opponent in the
scientific race for their knowledge is the multi-billion dollar
pharmaceutical industry with every resource in the world at
its disposal."'
Yet biocolonialism continues despite the fact that no
international legal body contains the resources or desire to
regulate it.' 98 The CBD, with some alteration, remains the
most viable candidate to regulate the biotechnology
industry.9 Its approach, giving consideration to both the
indigenous perspective and the scientific community, is the
192. Whitt, supra note 5, at 238. ('In Maori, 'a gene' is translated as
iratangata - 'life spirit of mortals.'").
193. See Whitt, supra note 5, at 238.
194. See Morrison Institute FAQ, supra note 6.
195. See Whitt, supra note 5.
196. See id.
197. See RAFI, supra note 79.
198. See RAFI, supra note 44.
199. See Convention on Biological Diversity, supra note 148.
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best chance for a responsible international policy to govern
the biotechnology industry in the 21st century.
